[
  {
    "ts": "2025-12-10T10:52:03+00:00",
    "headline": "Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend",
    "summary": "Gilead Sciences, Inc. ( NASDAQ:GILD ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one...",
    "url": "https://finance.yahoo.com/news/heres-gilead-sciences-nasdaq-gild-105203738.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "80c5c376-acd1-3448-b36e-3455768f16ea",
      "content": {
        "id": "80c5c376-acd1-3448-b36e-3455768f16ea",
        "contentType": "STORY",
        "title": "Here's What We Like About Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend",
        "description": "",
        "summary": "Gilead Sciences, Inc. ( NASDAQ:GILD ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is one...",
        "pubDate": "2025-12-10T10:52:03Z",
        "displayTime": "2025-12-10T10:52:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HAEiJmFsYXJTRBPxnneP6w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXB9F2qU7k4qk3_k1DQd9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/34a971ca153ed4a9b10f7d789bca1b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-gilead-sciences-nasdaq-gild-105203738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-gilead-sciences-nasdaq-gild-105203738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T16:28:46+00:00",
    "headline": "Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD)",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on December 7, setting a price target of $135. The same day, Kite, a Gilead Sciences, Inc. (NASDAQ:GILD) company, released a new analysis showing that second-line Yescarta therapy […]",
    "url": "https://finance.yahoo.com/news/cantor-fitzgerald-maintains-buy-rating-162846108.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "746e1dbf-dd93-3bbe-b4cb-76d79cec6280",
      "content": {
        "id": "746e1dbf-dd93-3bbe-b4cb-76d79cec6280",
        "contentType": "STORY",
        "title": "Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD)",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould maintained a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) on December 7, setting a price target of $135. The same day, Kite, a Gilead Sciences, Inc. (NASDAQ:GILD) company, released a new analysis showing that second-line Yescarta therapy […]",
        "pubDate": "2025-12-10T16:28:46Z",
        "displayTime": "2025-12-10T16:28:46Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Why Gilead Sciences (GILD) Deserves Attention in the Cheap Quarterly Dividend Stocks Category",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ha22PhpGlsEhK3tmOzGDVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CkBvnQJGKRIUyIDAWZszGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/11c0338c5011aa20a9d44b77386b4a12.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-maintains-buy-rating-162846108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-maintains-buy-rating-162846108.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T20:00:00+00:00",
    "headline": "New Study: Integrative Therapy and Nurse Navigation Reduce Treatment Side Effects for 75% of Black Breast Cancer Patients; 85% Report Lower Distress",
    "summary": "ANNAPOLIS, Md. & PHILADELPHIA, December 10, 2025--Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and critical research addressing health disparities, entitled \"A New Comprehensive Integrative Care and Navigation Model for Enhancing Outcomes for Black Breast Cancer Patients: Evidence from the Care for HER Program​\" at the 2025 San Antonio Breast Cancer Symposium.",
    "url": "https://finance.yahoo.com/news/study-integrative-therapy-nurse-navigation-200000375.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "c4efaadd-7167-3471-ae43-c76b89a4f55f",
      "content": {
        "id": "c4efaadd-7167-3471-ae43-c76b89a4f55f",
        "contentType": "STORY",
        "title": "New Study: Integrative Therapy and Nurse Navigation Reduce Treatment Side Effects for 75% of Black Breast Cancer Patients; 85% Report Lower Distress",
        "description": "",
        "summary": "ANNAPOLIS, Md. & PHILADELPHIA, December 10, 2025--Leading breast cancer nonprofits Unite for HER and TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA) presented new and critical research addressing health disparities, entitled \"A New Comprehensive Integrative Care and Navigation Model for Enhancing Outcomes for Black Breast Cancer Patients: Evidence from the Care for HER Program​\" at the 2025 San Antonio Breast Cancer Symposium.",
        "pubDate": "2025-12-10T20:00:00Z",
        "displayTime": "2025-12-10T20:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/3f68d8b8cb730798963337d4982374ca",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cKzLyMZyRDYyiRPZuw2.bg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/3f68d8b8cb730798963337d4982374ca.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/COBhoTO3rV5ac4RdxbtTWg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/3f68d8b8cb730798963337d4982374ca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/study-integrative-therapy-nurse-navigation-200000375.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/study-integrative-therapy-nurse-navigation-200000375.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DSKYF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]